TICKERNOMICS Sign up
Last Update: 2023-12-23 05:57:19
NOVO NORDISK A S ( NVO ) https://www.novonordisk.com
103.48USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
Denmark
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
-22.31%
NVO
SPY
30.72%
NVO
54.87%
SPY
112.82%
NVO
160.33%
SPY
201.04%
NVO
263.25%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
464521.72
480220.72
3.34
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
15.51
5.76
5.00
7.93
0.60
12.45
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
45.82
83.46
47.81
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
5.6402
313.30
383.93
0.43
Other Earnings and Cash Flow Stats:
NOVO NORDISK A S ( NVO ) Net Income TTM ($MM) is 29130.00
NOVO NORDISK A S ( NVO ) Operating Income TTM ($MM) is 34418.91
NOVO NORDISK A S ( NVO ) Owners' Earnings Annual ($MM) is 0.00
NOVO NORDISK A S ( NVO ) Current Price to Owners' Earnings ratio is 0.00
NOVO NORDISK A S ( NVO ) EBITDA TTM ($MM) is 38087.27
NOVO NORDISK A S ( NVO ) EBITDA Margin is 47.81%
Capital Allocation:
NOVO NORDISK A S ( NVO ) has paid 0.62 dividends per share and bought back -2220.5 million shares in the past 12 months
NOVO NORDISK A S ( NVO ) has increased its debt by 29505.625684126 million USD in the last 12 months
Capital Structure:
NOVO NORDISK A S ( NVO ) Interest-bearing Debt ($MM) as of last quarter is 33150
NOVO NORDISK A S ( NVO ) Annual Working Capital Investments ($MM) are -79986
NOVO NORDISK A S ( NVO ) Book Value ($MM) as of last quarter is 92991
NOVO NORDISK A S ( NVO ) Debt/Capital as of last quarter is 35%
Other Balance Sheet Stats:
NOVO NORDISK A S ( NVO ) has 30144 million in cash on hand as of last quarter
NOVO NORDISK A S ( NVO ) has 172552 million of liabilities due within 12 months, and long term debt 26537 as of last quarter
NOVO NORDISK A S ( NVO ) has 4489 common shares outstanding as of last quarter
NOVO NORDISK A S ( NVO ) has 0 million USD of preferred stock value
Academic Scores:
NOVO NORDISK A S ( NVO ) Altman Z-Score is 2.31 as of last quarter
NOVO NORDISK A S ( NVO ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
NOVO NORDISK A S ( NVO ) largest shareholder is Fayez Sarofim & Company owning 11603964 shares at 1200.78 ($MM) value
Eric S Sprott(an insider) Bought 50000 shares of NOVO NORDISK A S ( NVO ) for the amount of $417000.00 on 2017-11-08
0.01% of NOVO NORDISK A S ( NVO ) is held by insiders, and 8.22% is held by institutions
NOVO NORDISK A S ( NVO ) went public on 1982-01-04
Other NOVO NORDISK A S ( NVO ) financial metrics:
FCF:36981.04
Unlevered Free Cash Flow:0.00
EPS:20.03
Operating Margin:45.82
Gross Profit Margin:83.46
Div. Payout Ratio%:9.36
Div. Growth YoY%:9.78
Equity Return%:96.69
Beta:0.43
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About NOVO NORDISK A S ( NVO ) :
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.